GTCR-backed TerSera Therapeutics to acquire Xermelo business from Lexicon Pharmaceuticals, for $159m.

GTCR-backed TerSera Therapeutics, a drug manufacturer, agreed to acquire Xermelo business from Lexicon Pharmaceuticals, a pharmaceutical company, for $159m. "Xermelo is a great addition to the TerSera portfolio, which now includes six commercial products in two attractive therapeutic areas. This acquisition further demonstrates our commitment to the Leaders Strategy™, having partnered with Ed three times and built three unique, growing specialty pharmaceutical companies," Dean Mihas, GTCR Managing Director.